Lab21 appoints Susan Lowther as Chief Financial Officer
Posted: 27 October 2010 | | No comments yet
Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine is pleased to announce the appointment of Susan Lowther as Chief Financial Officer.
Susan brings a wealth of experience, gained over 20 years in the pharmaceutical, biotech and healthcare industries. She has extensive financial management expertise, gained from working with start up companies to global PLCs, covering both public and private financing, including venture capital financing and IPOs. Susan also has extensive experience of M&A activity, including acquisition and divestment.
Susan has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 CEO commented: ‘Lab21 is now well established with facilities in both the UK and US, a large international customer base, and an expanding portfolio of products and services. Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company. I would also like to thank Maddy Kennedy, our previous CFO, whose contributions to the business have had a huge impact in ensuring Lab21 is in a strong position for future growth.’
Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine is pleased to announce the appointment of Susan Lowther as Chief Financial Officer.
Susan brings a wealth of experience, gained over 20 years in the pharmaceutical, biotech and healthcare industries. She has extensive financial management expertise, gained from working with start up companies to global PLCs, covering both public and private financing, including venture capital financing and IPOs. Susan also has extensive experience of M&A activity, including acquisition and divestment.
Susan has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 CEO commented: ‘Lab21 is now well established with facilities in both the UK and US, a large international customer base, and an expanding portfolio of products and services. Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company. I would also like to thank Maddy Kennedy, our previous CFO, whose contributions to the business have had a huge impact in ensuring Lab21 is in a strong position for future growth.’
